Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 60.
A
Abbosh, C;
Birkbak, NJ;
Wilson, GA;
Jamal-Hanjani, M;
Constantin, T;
Salari, R;
Le Quesne, J;
... Dessimoz, C; + view all
(2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Nature
, 545
pp. 446-451.
10.1038/nature22364.
|
|
Ahern, AL;
Wheeler, GM;
Aveyard, P;
Boyland, EJ;
Halford, JCG;
Mander, AP;
Woolston, J;
... Jebb, SA; + view all
(2017)
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial.
The Lancet
, 389
(10085)
pp. 2214-2225.
10.1016/S0140-6736(17)30647-5.
|
 |
B
|
Bookman, MA;
Okamoto, A;
Stuart, G;
Yanaihara, N;
Aoki, D;
Bacon, M;
Fujiwara, K;
... Ochiai, K; + view all
(2017)
Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference.
Annals of Oncology
, 28
(S8)
viii30-viii35.
10.1093/annonc/mdx449.
|
|
Bray, TJP;
Singh, S;
Latifoltojar, A;
Rajesparan, K;
Rahman, F;
Narayanan, P;
Naaseri, S;
... Hall-Craggs, MA; + view all
(2017)
Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study.
PLoS One
, 12
(7)
, Article e0180562. 10.1371/journal.pone.0180562.
|
C
|
Cameron, AJM;
Veeriah, S;
Marshall, JJT;
Murray, ER;
Larijani, B;
Parker, PJ;
(2017)
Uncoupling TORC2 from AGC kinases inhibits tumour growth.
Oncotarget
, 8
(49)
pp. 84685-84696.
10.18632/oncotarget.20086.
|
|
|
Coleman, RL;
Oza, AM;
Lorusso, D;
Aghajanian, C;
Oaknin, A;
Dean, A;
Colombo, N;
... ARIEL3 investigators; + view all
(2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet
, 390
(10106)
pp. 1949-1961.
10.1016/S0140-6736(17)32440-6.
|
|
Counsell, N;
Biri, D;
Fraczek, J;
Hackshaw, A;
(2017)
Publishing interim results of randomised clinical trials in peer-reviewed journals.
Clinical Trials
, 14
(1)
pp. 67-77.
10.1177/1740774516664689.
|
|
D
|
Dehbi, H-M;
Royston, P;
Hackshaw, A;
(2017)
Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards.
BMJ
(357)
, Article j2250. 10.1136/bmj.j2250.
|
|
|
Dougherty, BA;
Lai, Z;
Hodgson, DR;
Orr, MCM;
Hawryluk, M;
Sun, J;
Yelensky, R;
... Barrett, JC; + view all
(2017)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
Oncotarget
, 8
(27)
pp. 43653-43661.
10.18632/oncotarget.17613.
|
F
|
Fotopoulou, C;
Hall, M;
Cruickshank, D;
Gabra, H;
Ganesan, R;
Hughes, C;
Kehoe, S;
... Sundar, S; + view all
(2017)
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.
European Journal of Obstetrics & Gynecology and Reproductive Biology
, 213
pp. 123-139.
10.1016/j.ejogrb.2017.04.016.
|
|
|
Fresneau, B;
Hackshaw, A;
Hawkins, DS;
Paulussen, M;
Anderson, JR;
Judson, I;
Litiere, S;
... Le Teuff, G; + view all
(2017)
Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).
Pediatric Blood & Cancer
, 64
(8)
, Article e26457. 10.1002/pbc.26457.
|
|
G
|
Gleeson, M;
Counsell, N;
Cunningham, D;
Chadwick, N;
Lawrie, A;
Hawkes, EA;
McMillan, A;
... Linch, D; + view all
(2017)
Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.
Annals of Oncology
, 28
(10)
pp. 2511-2516.
10.1093/annonc/mdx353.
|
|
|
Glynne-Jones, R;
Adams, R;
Lopes, A;
Meadows, H;
(2017)
Clinical endpoints in trials of chemoradiation for patients with anal cancer.
[Review].
Lancet Oncology
, 18
(4)
E218-E227.
10.1016/S1470-2045(17)30190-0.
|
|
|
Glynne-Jones, R;
Sebag-Montefiore, D;
Meadows, HM;
Cunningham, D;
Begum, R;
Adab, F;
Benstead, K;
... Kadalayil, L; + view all
(2017)
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.
LANCET ONCOLOGY
, 18
(3)
pp. 347-356.
10.1016/S1470-2045(17)30071-2.
|
|
|
Gollins, S;
West, N;
Sebag-Montefiore, D;
Myint, AS;
Saunders, M;
Susnerwala, S;
Quirke, P;
... Beare, S; + view all
(2017)
Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
British Journal of Cancer
, 117
(9)
pp. 1286-1294.
10.1038/bjc.2017.294.
|
|
H
|
Halaska, MJ;
Haidopoulos, D;
Guyon, F;
Morice, P;
Zapardiel, I;
Kesic, V;
Cibula, D;
... Laky, R; + view all
(2017)
European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation.
International Journal of Gynecological Cancer
, 27
(1)
pp. 189-192.
10.1097/IGC.0000000000000911.
|
|
Hill, Mark Stephen;
(2017)
The genetic basis of sexual antagonism in Drosophila melanogaster.
Doctoral thesis , UCL (University College London).
|
|
Hirst, Y;
Skrobanski, H;
Kerrison, RS;
Kobayashi, LC;
Counsell, N;
Djedovic, N;
Ruwende, J;
... von Wagner, C; + view all
(2017)
Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial.
British Journal of Cancer
, 116
pp. 1408-1414.
10.1038/bjc.2017.117.
|
J
|
Jamal-Hanjani, M;
Wilson, GA;
McGranahan, N;
Birkbak, NJ;
Watkins, TBK;
Veeriah, S;
Shafi, S;
... Swanton, C; + view all
(2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer.
New England Journal of Medicine
, 376
(22)
pp. 2109-2121.
10.1056/NEJMoa1616288.
|
|
Jang, JYA;
Yanaihara, N;
Pujade-Lauraine, E;
Mikami, Y;
Oda, K;
Bookman, M;
Ledermann, J;
... Okamoto, A; + view all
(2017)
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference.
Journal of Gynecologic Oncology
, 28
(4)
, Article e54. 10.3802/jgo.2017.28.e54.
|
K
|
Karam, A;
Ledermann, JA;
Kim, J-W;
Sehouli, J;
Lu, K;
Gourley, C;
Katsumata, N;
... Ochiai, K; + view all
(2017)
Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
Annals of Oncology
, 28
(4)
pp. 711-717.
10.1093/annonc/mdx011.
|
|
Kerrison, RS;
McGregor, LM;
Marshall, S;
Isitt, J;
Counsell, N;
Rees, CJ;
von Wagner, C;
(2017)
Improving uptake of flexible sigmoidoscopy screening: a randomized trial of nonparticipant reminders in the English Screening Programme.
Endoscopy
, 49
(1)
pp. 35-43.
10.1055/s-0042-118452.
|
|
|
King, J;
Palmer, DH;
Johnson, P;
Ross, P;
Hubner, RA;
Sumpter, K;
Darby, S;
... Meyer, T; + view all
(2017)
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit.
Clinical Oncology
, 29
(4)
pp. 256-262.
10.1016/j.clon.2016.11.012.
|
|
Kühnl, A;
Cunningham, D;
Counsell, N;
Hawkes, EA;
Qian, W;
Smith, P;
Chadwick, N;
... Linch, D; + view all
(2017)
Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
Annals of Oncology
, 28
(7)
pp. 1540-1546.
10.1093/annonc/mdx128.
|
|
Kularatne, BY;
(2017)
The identification of novel biomarkers to guide treatment in endometrial cancer.
Doctoral thesis , UCL (University College London).
|
L
|
Lanceley, A;
Berzuini, C;
Burnell, M;
Gessler, S;
Morris, S;
Ryan, A;
Ledermann, JA;
(2017)
Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches.
International Journal of Gynecological Cancer
, 27
(1)
pp. 59-68.
10.1097/IGC.0000000000000877.
|
|
Ledermann, JA;
(2017)
Front-line therapy of advanced ovarian cancer: new approaches.
Annals of Oncology
, 28
(Suppl. 8)
viii46-viii50.
10.1093/annonc/mdx452.
|
|
Lheureux, S;
Lai, Z;
Dougherty, BA;
Runswick, S;
Hodgson, DR;
Timms, KM;
Lanchbury, JS;
... Oza, AM; + view all
(2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Clinical Cancer Research
, 23
(15)
pp. 4086-4094.
10.1158/1078-0432.CCR-16-2615.
|
|
Lim, EL;
Trinh, DL;
Ries, RE;
Wang, J;
Gerbing, RB;
Ma, Y;
Topham, J;
... Marra, MA; + view all
(2017)
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
Journal of Clinical Oncology
, 35
(35)
pp. 3964-3977.
10.1200/JCO.2017.74.7451.
|
 |
|
Linch, M;
Goh, G;
Hiley, C;
Shanmugabavan, Y;
McGranahan, N;
Rowan, A;
Wong, YNS;
... Swanton, C; + view all
(2017)
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Annals of Oncology
, 28
(10)
pp. 2472-2480.
10.1093/annonc/mdx355.
|
M
|
Marchetti, C;
Kristeleit, R;
McCormack, M;
Mould, T;
Olaitan, A;
Widschwendter, M;
MacDonald, N;
(2017)
Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review.
Gynecologic Oncology
, 144
(1)
pp. 57-60.
10.1016/j.ygyno.2016.11.001.
|
|
McGranahan, N;
Rosenthal, R;
Hiley, CT;
Rowan, AJ;
Watkins, TBK;
Wilson, GA;
Birkbak, NJ;
... Swanton, C; + view all
(2017)
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Cell
10.1016/j.cell.2017.10.001.
(In press).
|
|
|
McNamara, MG;
Bridgewater, J;
Lopes, A;
Wasan, H;
Malka, D;
Jensen, LH;
Okusaka, T;
... Valle, JW; + view all
(2017)
Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials.
BMC Cancer
, 17
, Article 262. 10.1186/s12885-017-3266-9.
|
|
|
Megias, D;
Phillips, M;
Clifton-Hadley, L;
Harron, E;
Eaton, DJ;
Sanghera, P;
Whitfield, G;
(2017)
Dose specification for hippocampal sparing whole brain radiotherapy (HS WBRT): considerations from the UK HIPPO trial QA programme.
British Journal Of Radiology
, 90
(1071)
, Article 20160829. 10.1259/bjr.20160829.
|
|
|
Milani, A;
Kristeleit, R;
McCormack, M;
Raja, F;
Luvero, D;
Widschwendter, M;
MacDonald, N;
... Ledermann, JA; + view all
(2017)
Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy.
ESMO Open
, 1
(6)
, Article e000117. 10.1136/esmoopen-2016-000117.
|
|
Miller, R;
Devlin, M-J;
Brown, NF;
Grunewald, T;
McCormack, M;
Lockley, M;
Ledermann, JA;
... Kristeleit, RS; + view all
(2017)
Outcome of patients with advanced endometrial and cervical cancer treated in a phase 1 unit.
Presented at: 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA.
|
|
|
Miller, RE;
Devlin, M;
Brown, N;
Woo, K;
Grunewald, T;
Speirs, A;
Mitchison, M;
... Kristeleit, R; + view all
(2017)
Guidance by molecular selection improves the outcome of early phase treatment for gynecological (GYN) cancers.
Presented at: AACR Annual Meeting 2017, Washington, D.C., USA.
|
|
Miller, RE;
Ledermann, JA;
(2017)
The European Society for Medical Oncology (ESMO) Congress 2016: Highlights and summary of selected abstracts in gynecologic cancers.
Gynecologic Oncology
, 144
(1)
pp. 8-10.
10.1016/j.ygyno.2016.11.040.
|
O
|
Orrell, M;
Yates, L;
Leung, P;
Kang, S;
Hoare, Z;
Whitaker, C;
Burns, A;
... Orgeta, V; + view all
(2017)
The impact of individual Cognitive Stimulation Therapy (iCST) on cognition, quality of life, caregiver health, and family relationships in dementia: A randomised controlled trial.
PLoS Medicine
, 14
(3)
, Article e1002269. 10.1371/journal.pmed.1002269.
|
P
|
Phillips, EH;
Nash, S;
Adedayo, T;
Whelan, CJ;
Fontana, M;
Mahmood, S;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2017)
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.
Amyloid
, 24
(4)
pp. 250-252.
10.1080/13506129.2017.1385453.
|
|
Pujade-Lauraine, E;
Ledermann, JA;
Selle, F;
Gebski, V;
Penson, RT;
Oza, AM;
Korach, J;
... SOLO2/ENGOT-Ov21 Investigators, .; + view all
(2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
The Lancet Oncology
, 18
(9)
pp. 1274-1284.
10.1016/S1470-2045(17)30469-2.
|
R
|
Raine, R;
Atkin, W;
Von Wagner, C;
Duffy, S;
Kralj-Hans, I;
Hackshaw, A;
Counsell, N;
... Wardle, J; + view all
(2017)
Testing innovative strategies to reduce the social gradient in the uptake of bowel cancer screening: a programme of four qualitatively enhanced randomised controlled trial.
Programme Grants for Applied Research
, 5
(8)
10.3310/pgfar05080.
|
|
|
Read, ML;
Fong, JC;
Modasia, B;
Fletcher, A;
Imruetaicharoenchoke, W;
Thompson, RJ;
Nieto, H;
... McCabe, CJ; + view all
(2017)
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer.
Oncogene
, 36
(37)
pp. 5296-5308.
10.1038/onc.2017.154.
|
|
|
Reuter, M;
Camus, MF;
Hill, MS;
Ruzicka, F;
Fowler, K;
(2017)
Evolving Plastic Responses to External and Genetic Environments.
Trends in Genetics
, 33
(3)
pp. 169-170.
10.1016/j.tig.2017.01.004.
|
|
Roncolato, FT;
Joly, F;
O'Connell, R;
Lanceley, A;
Hilpert, F;
Buizen, L;
Okamoto, A;
... Friedlander, M; + view all
(2017)
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
The Oncologist
, 22
(9)
pp. 1117-1124.
10.1634/theoncologist.2017-0047.
|
|
Rossig, C;
Pule, M;
Altvater, B;
Saiagh, S;
Wright, G;
Ghorashian, S;
Clifton-Hadley, L;
... Amrolia, PJ; + view all
(2017)
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia.
Leukemia
, 31
pp. 1087-1095.
10.1038/leu.2017.39.
|
|
Ruers, T;
Van Coevorden, F;
Punt, CJA;
Pierie, J-PEN;
Borel-Rinkes, I;
Ledermann, JA;
Poston, G;
... and the National Cancer Research Institute Colorectal Clinical S, .; + view all
(2017)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
JNCI: Journal of the National Cancer Institute
, 109
(9)
, Article djx015. 10.1093/jnci/djx015.
|
|
S
|
Seckl, MJ;
Ottensmeier, CH;
Cullen, M;
Schmid, P;
Ngai, Y;
Muthukumar, D;
Thompson, J;
... Hackshaw, A; + view all
(2017)
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Journal of Clincal Oncology
, Article 2016697391. 10.1200/JCO.2016.69.7391.
|
|
|
Shankar, AG;
Roques, G;
Kirkwood, AA;
Lambilliotte, A;
Freund, K;
Leblanc, T;
Hayward, J;
... Landman-Parker, J; + view all
(2017)
Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
British Journal of Haematology
, 177
(1)
pp. 106-115.
10.1111/bjh.14518.
|
|
|
Smith, SG;
Wardle, J;
Atkin, W;
Raine, R;
McGregor, L;
Vart, G;
Morris, S;
... von Wagner, C; + view all
(2017)
Reducing the socioeconomic gradient in uptake of the NHS Bowel Cancer Screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.
BMC Cancer
, 17
, Article 543. 10.1186/s12885-017-3512-1.
|
|
|
Stark, D;
Cook, A;
Brown, J;
Brundage, M;
Embleton, A;
Kaplan, R;
Raja, F;
... Ledermann, J; + view all
(2017)
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Cancer
, 123
(14)
pp. 2752-2761.
10.1002/cncr.30657.
|
|
Szlosarek, PW;
Steele, JP;
Nolan, L;
Gilligan, D;
Taylor, P;
Spicer, J;
Lind, M;
... Hackshaw, A; + view all
(2017)
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma A Randomized Clinical Trial.
JAMA Oncology
, 3
(1)
pp. 58-66.
10.1001/jamaoncol.2016.3049.
|
T
|
Tan, WS;
Feber, A;
Dong, L;
Sarpong, R;
Rezaee, S;
Rodney, S;
Khetrapal, P;
... Kelly, JD; + view all
(2017)
DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
BMC Cancer
, 17
, Article 767. 10.1186/s12885-017-3758-7.
|
|
|
Turajlic, S;
Litchfield, K;
Xu, H;
Rosenthal, R;
McGranahan, N;
Reading, JL;
Wong, YNS;
... Swanton, C; + view all
(2017)
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.
The Lancet Oncology
, 18
(8)
pp. 1009-1021.
10.1016/S1470-2045(17)30516-8.
|
|
V
|
Vargas, FA;
Furness, AJS;
Solomon, I;
Joshi, K;
Mekkaoui, L;
Lesko, MH;
Rota, EM;
... Quezada, SA; + view all
(2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Immunity
, 46
(4)
pp. 577-586.
10.1016/j.immuni.2017.03.013.
|
|
|
Vivekanandan, S;
Landau, DB;
Counsell, N;
Warren, DR;
Khwanda, A;
Rosen, SD;
Parsons, E;
... Fenwick, JD; + view all
(2017)
The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer.
International Journal of Radiation Oncology Biology Physics
, 99
(1)
pp. 51-60.
10.1016/j.ijrobp.2017.04.026.
|
|
W
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
(2017)
Toxicity-dependent feasibility bounds for the Escalation with Overdose Control approach in phase I cancer trials.
Statistics in Medicine
, 36
(16)
pp. 2499-2513.
10.1002/sim.7280.
|
|
|
Wheeler, GM;
Sweeting, MJ;
Mander, AP;
Lee, SM;
Cheung, YKK;
(2017)
Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Statistics in Medicine
, 36
(2)
pp. 225-241.
10.1002/sim.6912.
|
|
|
Wong, YNS;
Joshi, K;
Pule, M;
Peggs, KS;
Swanton, C;
Quezada, SA;
Linch, M;
(2017)
Evolving adoptive cellular therapies in urological malignancies.
Lancet Oncology
, 18
(6)
E341-E353.
10.1016/S1470-2045(17)30327-3.
|
|
Y
|
Yang, Z;
Hackshaw, A;
Feng, Q;
Fu, X;
Zhang, Y;
Mao, C;
Tang, J;
(2017)
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
International Journal of Cancer
, 140
(12)
pp. 2805-2819.
10.1002/ijc.30691.
|
|
